 This study demonstrates that a comprehensive genomic profiling assay targeting 1.1 megabits of coding genome can accurately assess tumor mutation burden, TMB, which is a predictive biomarker of response to immune checkpoint inhibitor therapies. This methodology was used to analyze data from 100,000 cancer cases and found that a significant number of patients had high TMB, suggesting that these patients could potentially benefit from immunotherapy treatments. Additionally, the authors identified a cluster of somatic mutations in the promoter region of the gene PMS2, which occurs in 10% of skin cancers and is highly associated with increased TMB. This article was authored by Sakhariyar Chalmers, Katelyn F. Connelly, David Fabrizio, and others.